44 completed, 3 unknown, 2 withdrawn, 1 recruiting. 19 Phase 1, 13 Phase 3, 9 Phase 4, 5 Phase 2, 2 Not applicable.
By phase and status
Follow Ethinyl Estradiol-Norgestrel Combination: new trials by email Literature Review of Ethinyl Estradiol-Norgestrel Combination trials Research Report on Ethinyl Estradiol-Norgestrel Combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Ethinyl Estradiol + Levonorgestrel, ABBV-722 - Healthy Volunteer | Phase 1 | Completed | 15 | 2026-03-27 | 2026-07-30 |
A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
ABBV-295, Levonorgestrel/Ethinyl Estradiol - Healthy Volunteer | Phase 1 | Completed | 20 | 2026-02-11 | 2026-08-31 |
A Study of Elenestinib in Healthy Adult Female Participants
Elenestinib, Midazolam, Levonorgestrel/Ethinyl Estradiol - Healthy Participants | Phase 1 | Completed | 20 | 2026-02-05 | 2026-04-20 |
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
PF-08049820, Midazolam, Dabigatran Etexilate - Atopic Dermatitis | Phase 1 | Completed | 16 | 2025-10-03 | 2026-09-09 |
A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives
Ethinyl Estradiol / Levonorgestrel Oral Tablet, Aprocitentan - Drug Drug Interaction | Phase 1 | Completed | 19 | 2025-01-18 | 2025-03-11 |
An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions
AZD0780, Itraconazole, Carbamazepine - Dyslipidaemia | Phase 1 | Completed | 59 | 2024-09-25 | 2025-04-27 |
A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
Povorcitinib, Levonorgestrel/Ethinyl estradiol - Healthy Participants | Phase 1 | Completed | 24 | 2024-05-07 | 2024-07-03 |
Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
Vemircopan, Rosuvastatin, Metformin - Healthy Participants | Phase 1 | Completed | 60 | 2024-01-17 | 2025-08-12 |
A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)
MK-8527, LNG/EE - Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 1 | Completed | 14 | 2023-08-14 | 2025-01-20 |
A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System
Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System - Residual Drug Amount of EE and LNG | Phase 4 | Completed | 28 | 2021-10-25 | 2026-08-27 |
STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS
PF-06882961, Atorvastatin, Midazolam - Healthy Adults | Phase 1 | Completed | 35 | 2021-10-25 | 2024-08-19 |
Contraceptive Hormone and Reward Measurement (CHARM Study)
Levonorgestrel/ethinyl estradiol, Placebo - Oral Hormonal Contraceptive Use, Neural Activity | Phase 4 | Recruiting | 144 | 2021-10-01 | 2024-11-04 |
A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults
ABI-H2158, Itraconazole, Rifampin - Chronic Hepatitis B | Phase 1 | Completed | 80 | 2019-10-18 | 2020-03-04 |
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
Venetoclax, ethinyl estradiol/levonorgestrel - Hematologic Malignancies | Phase 1 | Unknown | 12 | 2019-07-30 | 2024-08-29 |
Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive
GSK3640254, Portia - HIV Infections | Phase 1 | Completed | 23 | 2019-06-13 | 2020-08-27 |
A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants
Ethinyl Estradiol + Levonorgestrel, JNJ-42847922 - Healthy | Phase 1 | Completed | 24 | 2017-08-14 | 2025-04-27 |
Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation
Ulipristal Acetate, Combined Oral Contraceptive Pill - Contraception | Phase 1 | Completed | 29 | 2016-12-16 | 2020-02-07 |
Impact of Combined Hormonal Contraceptives on UPA
Ulipristal Acetate, Levonorgestrel (LNG)/Ethinyl estradiol birth control pill - Contraception | Phase 4 | Completed | 36 | 2015-09-08 | 2019-11-08 |
A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods
Nur-Isterate, Nuvaring, Triphasil - HIV | Not applicable | Unknown | 131 | 2015-07-01 | 2019-02-11 |
Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.
LNG+EE2, Nordette - Irregular Periods | Phase 3 | Completed | 62 | 2014-07-01 | 2016-03-03 |
Showing 20 of 51. Sign in to see all of them.
Conditions studied
Menstruation Disturbances (3) · Premenstrual Syndrome (3) · Body Weight (2) · HIV Infections (2) · Metrorrhagia (2) · Acquired Immunodeficiency Syndrome (1) · Acromegaly (1) · Anorexia Nervosa (1) · Breast Neoplasms (1) · Contraception Behavior (1) · Dermatitis, Atopic (1) · Dyslipidemias (1) · Dysmenorrhea (1) · Hematologic Neoplasms (1) · Hepatitis B, Chronic (1)
Sponsors
Wyeth is now a wholly owned subsidiary of Pfizer (6) · Duramed Research (5) · AbbVie (3) · Bayer (3) · Oregon Health and Science University (3) · Pfizer (3) · AstraZeneca (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Abimbola Famuyide (1) · Agile Therapeutics (1) · Alexion Pharmaceuticals, Inc. (1) · Assembly Biosciences (1) · Azidus Brasil (1) · Blueprint Medicines Corporation (1) · Boston Children's Hospital (1)
Countries
United States (37) · Germany (3) · Brazil (2) · Canada (2) · Argentina (1) · Australia (1) · Belgium (1) · Chile (1) · Czechia (1) · Denmark (1) · Finland (1) · Mexico (1) · Netherlands (1) · Poland (1) · Romania (1)
Top investigators
Alison Edelman, MD, MPH (2) · Abimbola O. Famuyide, MBBS (1) · Alexandre Frederico, PI (1) · Alison Edelman, MD (1) · Andrew M Novick, MD PhD (1) · Anne Burke, MD MPH (1)
Results publications
PMID 20004272, PMID 10457868, PMID 11849631, PMID 11849634, PMID 12906905, PMID 18672111, PMID 19936155, PMID 21632810, PMID 21721593, PMID 22067793, PMID 23562364, PMID 23744513, PMID 24074027, PMID 24576794, PMID 24986712, PMID 25070547, PMID 25129340, PMID 25345427, PMID 25453585, PMID 26108094, PMID 27392467, PMID 27419258, PMID 27939877, PMID 28432403, PMID 29141040, PMID 32524605, PMID 32989170, PMID 33034421, PMID 33149114, PMID 35015210, PMID 35348351, PMID 37919697, PMID 8345046, PMID 8934059, PMID 9306028
NIH funding
2016 (1), R01HD043869 (1), R01HD061582 (1)